89889-52-1

Basic information

• Product Name: BIOTIN-XX-NHS
• Synonyms: N-SUCCINIMIDYL N-6-(BIOTINYLAMINO)CAP- &;6-(BIOTINAMIDOCAPROYLAMIDO)CAPROIC ACID N-HYDROXYSU;n-Succinimidyln-6-(biotinylamino)caproyl-6-aminocaproatabout90%;6-[6-(Biotinylamino)hexanoylamino]hexanoicacidN-hydroxysuccinimideester;5-[5-(N-SUCCINIMIDYLOXYCARBONYL)PENTYLAMIDO]HEXYL D-BIOTINAMIDE (BIOTIN-(AC5)2-OSU);6-((+)-Biotinamidohexanoylamino)hexanoic acid N-hydroxysuccinimide ester;Biotin-X-X-NHS, N-Succinimidyl N-[6-(biotinylamino)caproyl]-6-aminocaproate, 6-(Biotinamidocaproylamido)caproic acid N-hydroxysuccinimide ester;LC-LC-NHS-(+)-Biotin
• CAS NO: 89889-52-1
• Molecular Formula: C₂₀H₃₀N₄O₆S
• Molecular Weight: 567.7
• EINECS: 205-525-8
• Product Categories: Biotin Derivatives;Cross Linking Reagents
• Mol File: 89889-52-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 147-151°C
• Appearance: /powder
• Density: 1.29±0.1 g/cm3(Predicted)
• Storage Temp.: −20°C
• Solubility: DMF: 25 mg/mL
• PKA: 13.90±0.40(Predicted)
• Stability: Moisture Sensitive
• BRN: 8377428
• CAS DataBase Reference: BIOTIN-XX-NHS(CAS DataBase Reference)
• NIST Chemistry Reference: BIOTIN-XX-NHS(89889-52-1)
• EPA Substance Registry System: BIOTIN-XX-NHS(89889-52-1)

Safety Data

• WGK Germany: 3
• F: 10-21
• Hazardous Substances Data: 89889-52-1(Hazardous Substances Data)

Usage

Description

Biotin-LC-LC-NHS is a biotinylation reagent that contains an N-hydroxysuccinimide (NHS) moiety, which activates carboxylic acid groups on biotin to facilitate coupling reactions, and a 30.5 ? spacer to decrease steric hindrance. It has been used to biotinylate small molecules such as paclitaxel and coenzyme Q10 for use in binding site characterization.

Chemical Properties

White Solid

Uses

Different sources of media describe the Uses of 89889-52-1 differently. You can refer to the following data:
1. Biotinamidohexanoyl-6-aminohexanoic acid N-hydroxysuccinimide ester has been used in human IgM biotinylation.
2. A biotinylated cross-linking reagent.

Upstream product

• 60-32-2 6-aminohexanoic acid 
• 74124-79-1 di(succinimido) carbonate 
• 72040-64-3 N-(+)-biotinyl-6-aminocaproic acid 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 35013-72-0 biotin N-Hydroxysuccinimide ester 
• 1306616-52-3 cyanomethyl biotinate 
• 58-85-5 biotin 

Downstream Products

• 440358-98-5 N-{6-[3-(N-cholesteryl-2-nitrobenzenesulfonamido)propylamino]-6-oxohexyl}biotinamide 
• 1141894-56-5 C₆₇H₉₉N₉O₁₁S₂ 
• 1141894-57-6 C₆₇H₉₉N₉O₁₁S₂ 
• 1141486-32-9 C₆₇H₉₉N₉O₁₂S₂ 
• 1141486-33-0 C₆₉H₁₀₁N₉O₁₃S₂ 
• 1141486-17-0 C₆₉H₁₀₁N₉O₁₁S₂ 
• 1141486-40-9 C₆₉H₁₀₁N₉O₁₂S₂ 
• 1141486-41-0 C₆₉H₁₀₃N₉O₁₁S₂ 
• 226087-16-7 2-[4-({6-[5-((3aR,6S,6aS)-2-Oxo-hexahydro-thieno[3,4-d]imidazol-6-yl)-pentanoylamino]-hexanoylamino}-methyl)-benzoyl]-benzoic acid methyl ester 
• 89889-51-0 D-biotinylaminohexanoylaminohexanoic acid 

Relevant articles and documents

Synthesis and in?vitro anticancer activities of biotinylated derivatives of glaucocalyxin A and oridonin

Fourteen glaucocalyxin A biotinylated derivatives, one glaucocalyxin C biotinylated derivative, and two oridonin biotinylated derivatives were designed and synthesized. Their structures were confirmed from 1H NMR, 13C NMR and HRMS data. The derivatives were evaluated for cytotoxic activities against lung (A549), cervical cancer cell line HeLa derivative (KB), multidrug-resistant KB subline (KB-VIN), triple-negative breast (MDA-MB-231), and estrogen receptor-positive breast (MCF-7) cancer cell lines. (Figure presented.).

COMPOSITION AND METHODS FOR IMAGING CELLS

A composition for imaging a cell includes a first imaging probe and a second imaging probe that include respectively a first reporter moiety and a second reporter moiety. The first reporter moiety and the second reporter moiety form a signaling complex that produces a detectable signal when the first imaging probe and second imaging probe complex with first and second biomarkers of the cell.

BIOTIN-CONJUGATED N-ACETYL GLYCOL SPLIT HEPARIN

The present invention relates to N-acetyl glycol split heparin molecules conjugated with biotin having following formula (I), wherein the meanings of the substituents are disclosed in the description. The present invention also relates to such compounds for use as medicaments, in particular for the treatment of diseases and disorders associated with heparanase activity, and to pharmaceutical compositions comprising the same.